HST-1011

· HotSpot Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HST-1011, covering 2025-02-04 to 2025-02-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody [Phase 1, Phase 2]